Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Pulmonary Edema D011654 23 associated lipids
Coronary Disease D003327 70 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Pancreatitis D010195 10 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Rhinitis D012220 10 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Melanoma D008545 69 associated lipids
Asthma D001249 52 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Lee T et al. Increased biosynthesis of platelet-activating factor in activated human eosinophils. 1984 J. Biol. Chem. pmid:6425292
Hopkins NK et al. Acetyl glyceryl ether phosphorylcholine (PAF-acether) and leukotriene B4-mediated neutrophil chemotaxis through an intact endothelial cell monolayer. 1984 Biochim. Biophys. Acta pmid:6089913
Emilsson A and Sundler R Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and ionophore A23187. 1984 J. Biol. Chem. pmid:6321496
Hillmar I et al. Effects of a thio analog of platelet-activating factor on platelet aggregation and adenosine 3',5'-monophosphate concentration in hepatocyte suspensions and in platelets. A comparison with the naturally occurring compound. 1984 Hoppe-Seyler's Z. Physiol. Chem. pmid:6325321
Krishnamurthi S et al. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. 1984 Biochem. Pharmacol. pmid:6091666
Valone FH Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. 1984 Immunology pmid:6325330
Kramp W et al. Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. 1984 Chem. Phys. Lipids pmid:6744496
Smith RJ et al. Effects of an anion channel blocker, 4, 4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS), on human neutrophil function. 1984 Biochem. Biophys. Res. Commun. pmid:6329191
Lefort J et al. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. 1984 Br. J. Pharmacol. pmid:6430375
Kamitani T et al. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. 1984 Eur. J. Pharmacol. pmid:6144557
Tokumura A et al. Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. 1984 J. Pharm. Pharmacol. pmid:6144763
Pirotzky E et al. Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. 1984 Kidney Int. pmid:6144811
Gómez-Cambronero J et al. The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). 1984 Biochem. J. pmid:6146309
Morley J et al. The platelet in asthma. 1984 Lancet pmid:6150192
Kloprogge E and Akkerman JW Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. 1984 Biochem. J. pmid:6150705
Dahlbäck M et al. Bronchial anaphylaxis in actively sensitized Sprague Dawley rats: studies on mediators involved. 1984 Acta Pharmacol Toxicol (Copenh) pmid:6431753
Rao AK et al. Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. 1984 Am. J. Hematol. pmid:6431801
Colditz IG and Movat HZ Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. 1984 J. Immunol. pmid:6088633
Cervoni P et al. Evidence for the lack of interaction between (+/-)-1-O-octadecyl-2-acetylglyceryl-3-phosphorylcholine and alpha-adrenoceptors in vivo and in vitro. 1984 Br. J. Pharmacol. pmid:6091835
Fink KL and Gross RW Modulation of canine myocardial sarcolemmal membrane fluidity by amphiphilic compounds. 1984 Circ. Res. pmid:6091941
Kulikov VI and Bergel'son LD [Binding of 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (thrombocyte activating factor) by plasma components. Exchange of the thrombocyte activating factor between lipoproteins and thrombocytes]. 1984 Biokhimiia pmid:6093897
Haye B et al. Interactions between thyreostimulin and PAF-acether on thyroid cell metabolism. 1984 Eur. J. Pharmacol. pmid:6094205
Gordeev KIu et al. [A bioregulator of lipid nature--a platelet activating factor (PAF)]. 1984 Bioorg. Khim. pmid:6099122
Wang ZY [Advances in the physiopathology of platelets]. 1984 Zhonghua Nei Ke Za Zhi pmid:6099795
Clay KL et al. Structure elucidation of platelet activating factor derived from human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6430285
Siess W et al. Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change. 1984 J. Biol. Chem. pmid:6429141
Knauer KA et al. Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6200443
Kazimierczak W et al. Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. 1984 Am. Rev. Respir. Dis. pmid:6201094
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Willoughby WF and Willoughby JB Immunologic mechanisms of parenchymal lung injury. 1984 Environ. Health Perspect. pmid:6234162
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Nagata K et al. [Thrombotic thrombocytopenic purpura (TTP) with a remission following splenectomy after the failure of antiplatelet therapy and plasmapheresis]. 1984 Rinsho Ketsueki pmid:6542941
Pirotzky E et al. PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. 1984 Microcirc Endothelium Lymphatics pmid:6546141
Bussolino F et al. Platelet-activating factor phosphatidate, but not platelet-activating factor, is a powerful calcium ionophore in the human red cell. 1984 Cell Calcium pmid:6549153
Pirotzky E et al. Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyltransferase activity in isolated rat kidney cells. 1984 Lab. Invest. pmid:6492758
Handley DA et al. Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. 1984 Thromb. Haemost. pmid:6495262
Riess H and Hiller E Heparin and thrombocytopenia. 1984 Ann. Intern. Med. pmid:6497200
Blank ML et al. Conversion of 1-alkyl-2-acetyl-sn-glycerols to platelet activating factor and related phospholipids by rabbit platelets. 1984 Biochem. Biophys. Res. Commun. pmid:6497876
Lichey J et al. Pressure effects and uptake of platelet-activating factor in isolated rat lung. 1984 J Appl Physiol Respir Environ Exerc Physiol pmid:6501025
Buxton DB et al. Stimulation of glycogenolysis and platelet-activating factor production by heat-aggregated immunoglobulin G in the perfused rat liver. 1984 J. Biol. Chem. pmid:6501277
Mueller HW et al. The molecular species distribution of platelet-activating factor synthesized by rabbit and human neutrophils. 1984 J. Biol. Chem. pmid:6501307
Goldenberg MM and Meurer RD A pharmacologic analysis of the action of platelet-activating factor in the induction of hindpaw edema in the rat. 1984 Prostaglandins pmid:6505225
Wissner A et al. Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain. 1984 J. Med. Chem. pmid:6471071
Mallet AI et al. Rapid isocratic high-performance liquid chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. 1984 J. Chromatogr. pmid:6480761
Kenzora JL et al. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. 1984 J. Clin. Invest. pmid:6480824
Jackson EM et al. High performance liquid chromatography of platelet-activating factors. 1984 J. Lipid Res. pmid:6481248
Dewar A et al. Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig. 1984 J. Pathol. pmid:6481526
Goldstein BM et al. Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. 1984 Life Sci. pmid:6482659
Baldo BA and Tovey ER Allergy, allergens and allergen standardization. 1984 Med. J. Aust. pmid:6482786
Saeki S et al. Effect of 1-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine on blood pressure by intra-lateral ventricular injection in the rat. 1984 Med J Osaka Univ pmid:6482814
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Satouchi K et al. Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor. 1984 Arch. Biochem. Biophys. pmid:6486825
Chilton FH et al. 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. 1984 J. Biol. Chem. pmid:6434535
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Caramelo C et al. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. 1984 Biochem. Biophys. Res. Commun. pmid:6732788
Lenihan DJ and Lee TC Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6732789
Ludwig JC et al. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular Ca2+. 1984 Arch. Biochem. Biophys. pmid:6430234
Kasuya Y et al. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. 1984 Can. J. Physiol. Pharmacol. pmid:6733593
Page CP et al. Platelets and bronchospasm. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6735490
Söling HD et al. Acetylcholine-like effects of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine ('platelet-activating factor') and its analogues in exocrine secretory glands. 1984 Eur. J. Biochem. pmid:6207023
Jouvin-Marche E et al. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. 1984 J. Immunol. pmid:6736649
Renal syndromes and nonsteroidal antiinflammatory drugs. 1984 N. Engl. J. Med. pmid:6738607
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Hoffman DR et al. Cytotoxicity of ether-linked phytanyl phospholipid analogs and related derivatives in human HL-60 leukemia cells and polymorphonuclear neutrophils. 1984 Res. Commun. Chem. Pathol. Pharmacol. pmid:6739956
Levi R et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. 1984 Circ. Res. pmid:6692502
Humphrey DM et al. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. 1984 Lab. Invest. pmid:6694349
Masugi F et al. Effect of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the rat. 1984 Life Sci. pmid:6694519
Bottecchia D et al. Influence of the pure synthetic PAF (platelet aggregating factor) on clot retraction and platelet aggregation. 1984 Scand J Haematol pmid:6695148
Blank ML et al. A new class of antihypertensive neutral lipid: 1-alkyl-2-acetyl-sn-glycerols, a precursor of platelet activating factor. 1984 Biochem. Biophys. Res. Commun. pmid:6696762
Williams KA and Haslam RJ Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor). 1984 Biochim. Biophys. Acta pmid:6696908
Albert DH and Snyder F Release of arachidonic acid from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine, a precursor of platelet-activating factor, in rat alveolar macrophages. 1984 Biochim. Biophys. Acta pmid:6435681
Hoffman DR et al. Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts. 1984 Blood pmid:6696992
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
El Tamer A et al. Studies on ether phospholipids. I. A new method of determination using phospholipase A1 from guinea pig pancreas: application to Krebs II ascites cells. 1984 Biochim. Biophys. Acta pmid:6712966
Touqui L et al. Dissociation between inhibition of phospholipid methylation and production of PAF-acether by rabbit platelets. 1984 Experientia pmid:6714369
Masugi F et al. [Etiological studies of hypertension. G. APRL (antihypertensive polar renomedullary lipid)]. 1984 Nippon Rinsho pmid:6716685
Kester M et al. The potentiation of arterial contraction with platelet activating factor. 1984 Pflugers Arch. pmid:6718228
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Guay DR and Richard A Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. 1984 Drug Intell Clin Pharm pmid:6723517
Poitevin B et al. Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. 1984 Immunopharmacology pmid:6724877
Kawaguchi H and Yasuda H Platelet-activating factor stimulates phospholipase in quiescent Swiss mouse 3T3 fibroblast. 1984 FEBS Lett. pmid:6436057
Kasuya Y et al. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). 1984 J. Pharmacobio-dyn. pmid:6726619
Kramer RM et al. Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. 1984 J. Biol. Chem. pmid:6436245
McGivern DV and Basran GS Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in man. 1984 Eur. J. Pharmacol. pmid:6592097
Beaubien BB et al. Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. 1984 Biochem. Biophys. Res. Commun. pmid:6594998
Roubin R et al. The role of immunomodulators in the production of lipid mediators by macrophages (M phi). 1984 Int J Tissue React pmid:6596298
Archer CB et al. Inflammatory characteristics of platelet activating factor (PAF-acether) in human skin. 1984 Br. J. Dermatol. pmid:6581831
Andreesen R et al. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. 1984 J. Natl. Cancer Inst. pmid:6582303
Kornecki E et al. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. 1984 Science pmid:6150550
Chignard M et al. Paf-acether formation and arachidonic acid freeing from platelet ether-linked glyceryl-phosphorylcholine. 1984 Biochem. Biophys. Res. Commun. pmid:6437404
Schleimer RP et al. Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. 1984 J. Allergy Clin. Immunol. pmid:6208229
O'Neill C and Saunders DM Assessment of embryo quality. 1984 Lancet pmid:6149413
Bussolino F et al. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. 1984 Exp. Hematol. pmid:6333353
Nishihira J et al. Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. 1984 Lipids pmid:6527609
Lefer AM et al. Pathophysiological mechanisms of sudden death induced by platelet activating factor. 1984 Br. J. Pharmacol. pmid:6435705
Gunby P A new piece for the puzzle of inflammation. 1984 JAMA pmid:6420583
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930
Prevost MC et al. Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. 1984 Biochem. Biophys. Res. Commun. pmid:6422938